Velocity Clinical Research, Inc.’s Post

Attending Pri-Med West later this week in #Anaheim? Visit booth 432 to connect with Mary Hughes, Modesto Carrillo, Dafne Yagupsky, M.D., Maria Morales, John Nelson, Patricia Gonzalez, and Jennifer Huynh! Meet our team to learn more about clinical trials at Velocity, opportunities at our SoCal sites, and our capabilities across 90+ sites worldwide. #PriMedWest

Velocity has now paid more than $1.1 million in patient study stipends through our VISION Engage app. Here's why this matters: Patients get: • Prompt, secure in-app payments • Direct bank transfers or virtual debit card options • Enhanced visibility and flexibility Sites get: • Seamless integration with existing workflows • Reduced administrative burden • Improved patient satisfaction and retention Explore more about VISION, Velocity’s AI-enabled data and technology platform: https://lnkd.in/gpZECMhS Congratulations to Raghu Punnamraju, Sweta Pittala, Sneha Raj, PMP, and our entire team in Hyderabad for reaching this milestone! #VISION #AI #PatientRecruitment #ClinicalTrials

We’re approaching respiratory disease season and the start of large-scale vaccine trials worldwide. To support the growing scale and complexity of global vaccine research programs — and specialized oncology trials — Velocity provides 100% in-network peripheral blood mononuclear cell (PBMC) collection, processing, and analysis at more than 30 sites across the U.S. and Europe. Our global laboratory network and sites are equipped to: • Operate on-site, CLIA-certified laboratory facilities. • Follow established PBMC SOPs and customize PBMC handling for Sponsor protocols (≥95% viability, 0.8 -3.2 cell/mL yield). • Support GMO handling, including gene therapy, with Institutional Biosafety Committee (IBC) certification. • Provide continuous temperature monitoring with SmartSense by Digi technology, as well as ambient, refrigerated, and frozen sample handling (including -80°C and liquid nitrogen storage). Learn more about our global laboratory capabilities: https://lnkd.in/gjPkG372 Connect with Nick Spittal #Vaccines #COVID #Influenza #Flu #RSV #Oncology

Exciting news! Cognivue, Inc.'s FOCUS study results were just published in the Journal of Alzheimer’s Disease. Velocity is proud to have supported the study by enrolling all of its participants — more than 1,500 subjects across 14 sites and 11 states. The enrollment objective was to amass a group resembling the racial, ethnic, gender, and educational makeup recorded in the 2020 U.S. census data. Velocity far exceeded the national averages, enrolling more than 37% of participants from underrepresented populations.

Raghu Punnamraju, Chief Technology Officer at Velocity, was recently interviewed by CIO News about applying a lean-value approach to our technical product management, engineering, and architectural strategies. Through the development of our VISION platform, and new frameworks that leverage LLMs, this article details how Raghu and our team in Hyderabad, India, are continuously delivering solutions to drive greater recruitment efficiency and site performance. Read the article: https://lnkd.in/gRUp7gBq

Last month, Velocity welcomed former Surgeon General Jerome Adams, MD, MPH to an internal presentation about the importance and direction of diversity in clinical trial inclusion, followed by a Q&A hosted by Paul Evans. In this discussion, Dr. Adams made the argument that increasing diversity among the participants of clinical trials isn’t just morally right, it’s economically better for all involved in the process. Illustrating his point, Dr. Adams explained, “It was always assumed you had to pick one or the other in clinical trials; speed or diversity. To me, that is a false narrative. If you wait until the end to think about diversity then yes, it will slow you down. But what we showed with Warp Speed, which was the largest clinical trial in history, is that even if you come in midway and make a concerted effort, you can get there without slowing down the trials.” Hear more from Dr. Adams on topics like the intersection between economics and health, increasing equity in healthcare, and balancing politics with health in clinical research. #HealthEquity #DEI #VelocityCARES #ClinicalResearch

Wishing all a joyful and safe American Independence Day filled with family, friends, and cherished memories. Let's come together and appreciate the blessings of liberty that we enjoy. #FourthofJuly

Velocity is proud to introduce a new site in St. Louis, our first in Missouri. The site will be co-located with West County Rheumatology, one of the largest and most active infusion centers in the Midwest, and a region-leading clinic for patients with rheumatoid arthritis, psoriatic arthritis, lupus, fibromyalgia, and hypermobility disorders. An elected Fellow of the American College of Rheumatology, Sona Kamat, MD, FACR, will serve as Principal Investigator for clinical trials at Velocity. The site will provide specialized support for rheumatology research, as well as a growing array of internal medicine and multi-therapeutic trials. #Rheumatology #ClinicalTrials #ClinicalResearch

In this edition of The Recap, Craig Koch provides an insightful introduction to our recent milestones, and what they mean for Velocity — and the industry — moving forward. Topics include: • Velocity’s entry into the U.S. oncology market • Another major achievement for our VISION technology • Our expanding capabilities and team of Principal Investigators in the U.K. Subscribe to The Recap here on LinkedIn or at https://lnkd.in/grZdGsK4